文献速递肝病消化道肿瘤与早癌

spontaneous与治疗诱导的HBsAg清除长期临床结局比较

Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
PubMed 文献 · Hepatology · 2021-01-01

该回顾性队列研究纳入1,972例确认HBsAg清除的慢性乙型肝炎患者,比较自发(82.4%)与核苷(酸)类似物(NUC)诱导(17.6%)清除者的长期结局。倾向评分匹配后,两组HCC(P=0.52)和复合临床事件(P=0.14)风险无显著差异;但HBsAg清除后HCC年发生率0.38/100人年仍超过监测推荐阈值。

要点

  • NUC诱导与自发HBsAg清除者的HCC及临床事件风险无显著差异。
  • HBsAg清除后HCC年发生率为0.38/100人年,仍建议持续HCC监测。
  • 倾向评分匹配和多因素分析均支持上述主要结论。

核心结论

  • 自发与NUC诱导的HBsAg清除在HCC和复合临床事件风险上无显著差异。
  • HBsAg清除后HCC年风险仍超过推荐监测阈值,需继续HCC监测。

研究设计与样本

  • 回顾性分析1,972例至少间隔6个月连续两次确认HBsAg清除的慢性乙型肝炎患者。
  • 平均年龄53.7岁,男性占64.4%,肝硬化297例(15.1%)。
  • 自发清除1,624例(82.4%),NUC诱导清除348例(17.6%)。
  • 采用336对倾向评分匹配比较两组结局。

主要发现

  • 中位随访5.6年,49例发生HCC,年发生率0.38/100人年。
  • 倾向评分匹配后,NUC诱导与自发清除的HCC风险无显著差异(P=0.52)。
  • 倾向评分匹配后,两组复合临床事件风险无显著差异(P=0.14)。
  • 多因素分析:NUC诱导清除与HCC风险无显著关联(AHR 1.49,P=0.26)。
  • 多因素分析:NUC诱导清除与临床事件风险无显著关联(AHR 1.78,P=0.06)。

关键数值与推荐

  • HBsAg清除定义为至少间隔6个月连续两次确认。
  • 复合临床事件包括HCC、肝病相关死亡和肝移植。
  • HCC年发生率0.38/100人年超过推荐监测阈值。

临床怎么用

  • NUC诱导的HBsAg清除患者无需因清除方式不同而改变HCC监测策略。
  • HBsAg清除后仍应继续HCC监测,因年风险超过推荐阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HBsAg seroclearance is considered a realistic goal in patients with chronic hepatitis B (CHB), known as "functional cure." However, it remains elusive whether nucleos(t)ide analogue (NUC)-induced HBsAg seroclearance, compared with spontaneous HBsAg seroclearance, differs in its association with favorable long-term clinical outcomes. APPROACH AND RESULTS: A total of 1,972 CHB patients with confirmed HBsAg seroclearance at least two consecutive times, 6 months apart, were retrospectively analyzed. Risks of HCC development and composite clinical events, including HCC, liver-related death, and liver transplantation, were compared between spontaneous and NUC-induced HBsAg seroclearance. Of 1,972 patients, mean patient age was 53.7 years, and 64.4% were men. Cirrhosis was present in 297 (15.1%) patients. HBsAg seroclearance was achieved spontaneously in 1,624 (82.4%) patients and by NUC treatment in 348 (17.6%). HCC developed in 49 patients, with an annual incidence of 0.38 of 100 person-years (PY) during a median follow-up of 5.6 years. With 336 propensity-score-matched pairs, risks of HCC (P = 0.52) and clinical events (P = 0.14) were not significantly different between NUC-induced and spontaneous HBsAg seroclearance. By multivariable analysis, NUC-induced HBsAg seroclearance, compared with spontaneous HBsAg seroclearance, was not associated with the significantly higher risk of HCC (adjusted HR [AHR], 1.49; P = 0.26) and clinical events (AHR, 1.78; P = 0.06). CONCLUSIONS: Risks of HCC and clinical events were not significantly different between spontaneous and NUC-induced HBsAg seroclearance. Nonetheless, annual risk of HCC exceeds the recommended cutoff for HCC surveillance even after HBsAg seroclearance, suggesting that continued HCC surveillance is required.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Choi J, Yoo S, Lim YS, et al. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance. Hepatology. 2021. PMID: 33131063. doi:10.1002/hep.31610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。